These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib. Jedeszko C; Paez-Ribes M; Di Desidero T; Man S; Lee CR; Xu P; Bjarnason GA; Bocci G; Kerbel RS Sci Transl Med; 2015 Apr; 7(282):282ra50. PubMed ID: 25855496 [TBL] [Abstract][Full Text] [Related]
5. The prospects for combination therapy with capecitabine in the rapidly evolving treatment landscape of renal cell carcinoma. Bilen MA; Carlisle JW; Sonpavde G Expert Opin Investig Drugs; 2018 Feb; 27(2):163-170. PubMed ID: 29323560 [TBL] [Abstract][Full Text] [Related]
6. Cytotoxic chemotherapy in the treatment of advanced renal cell carcinoma in the era of targeted therapy. Diamond E; Molina AM; Carbonaro M; Akhtar NH; Giannakakou P; Tagawa ST; Nanus DM Crit Rev Oncol Hematol; 2015 Dec; 96(3):518-26. PubMed ID: 26321263 [TBL] [Abstract][Full Text] [Related]